Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A six-month periodic fasting reduces microalbuminuria and improves metabolic control in patients with type 2 diabetes and diabetic nephropathy: a randomized controlled study

View ORCID ProfileAlba Sulaj, Stefan Kopf, Ekaterina von Rauchhaupt, Elisabeth Kliemank, Maik Brune, Zoltan Kender, Hannelore Bartl, Fabiola Garcia Cortizo, Katarina Klepac, View ORCID ProfileZhe Han, Varun Kumar, Valter Longo, View ORCID ProfileAurelio Teleman, Jürgen G. Okun, View ORCID ProfileJakob Morgenstern, Thomas Fleming, Julia Szendroedi, Stephan Herzig, Peter P. Nawroth
doi: https://doi.org/10.1101/2021.12.01.21266958
Alba Sulaj
1Department of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1); Heidelberg University Hospital; Heidelberg 69120; Germany
2German Center of Diabetes Research (DZD); Neuherberg 85764; Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alba Sulaj
  • For correspondence: Alba.Sulaj@med.uni-heidelberg.de
Stefan Kopf
1Department of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1); Heidelberg University Hospital; Heidelberg 69120; Germany
2German Center of Diabetes Research (DZD); Neuherberg 85764; Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ekaterina von Rauchhaupt
1Department of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1); Heidelberg University Hospital; Heidelberg 69120; Germany
2German Center of Diabetes Research (DZD); Neuherberg 85764; Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabeth Kliemank
1Department of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1); Heidelberg University Hospital; Heidelberg 69120; Germany
2German Center of Diabetes Research (DZD); Neuherberg 85764; Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maik Brune
1Department of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1); Heidelberg University Hospital; Heidelberg 69120; Germany
3Joint Heidelberg-IDC Translational Diabetes Program, Helmholtz Center Munich; Neuherberg, 85764; Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zoltan Kender
1Department of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1); Heidelberg University Hospital; Heidelberg 69120; Germany
2German Center of Diabetes Research (DZD); Neuherberg 85764; Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hannelore Bartl
1Department of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1); Heidelberg University Hospital; Heidelberg 69120; Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabiola Garcia Cortizo
4German Cancer Research Center (DKFZ), Division of Signal Transduction in Cancer and Metabolism, Heidelberg 69120; Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katarina Klepac
5Institute for Diabetes and Cancer; Helmholtz Center Munich; Neuherberg, 85764; Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhe Han
1Department of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1); Heidelberg University Hospital; Heidelberg 69120; Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zhe Han
Varun Kumar
1Department of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1); Heidelberg University Hospital; Heidelberg 69120; Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valter Longo
6Longevity Institute, School of Gerontology, and Department of Biological Sciences, University of Southern California; Los Angeles, CA 90089-0191; USA
7FIRC Institute of Molecular Oncology, Italian Foundation for Cancer Research Institute of Molecular Oncology; 20139 Milan; Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aurelio Teleman
4German Cancer Research Center (DKFZ), Division of Signal Transduction in Cancer and Metabolism, Heidelberg 69120; Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Aurelio Teleman
Jürgen G. Okun
8Department of General Pediatrics, Division of Neuropediatrics and Metabolic Medicine, Centre for Pediatric and Adolescent Medicine; University Hospital Heidelberg; Heidelberg 69120; Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jakob Morgenstern
1Department of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1); Heidelberg University Hospital; Heidelberg 69120; Germany
2German Center of Diabetes Research (DZD); Neuherberg 85764; Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jakob Morgenstern
Thomas Fleming
1Department of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1); Heidelberg University Hospital; Heidelberg 69120; Germany
2German Center of Diabetes Research (DZD); Neuherberg 85764; Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Szendroedi
1Department of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1); Heidelberg University Hospital; Heidelberg 69120; Germany
2German Center of Diabetes Research (DZD); Neuherberg 85764; Germany
3Joint Heidelberg-IDC Translational Diabetes Program, Helmholtz Center Munich; Neuherberg, 85764; Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephan Herzig
2German Center of Diabetes Research (DZD); Neuherberg 85764; Germany
5Institute for Diabetes and Cancer; Helmholtz Center Munich; Neuherberg, 85764; Germany
9Joint Heidelberg-IDC Translational Diabetes Program, Internal Medicine 1; Heidelberg University Hospital; Heidelberg; 69120; Germany
10Chair Molecular Metabolic Control; Technical University Munich; Munich; 80333; Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter P. Nawroth
1Department of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1); Heidelberg University Hospital; Heidelberg 69120; Germany
2German Center of Diabetes Research (DZD); Neuherberg 85764; Germany
3Joint Heidelberg-IDC Translational Diabetes Program, Helmholtz Center Munich; Neuherberg, 85764; Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Aim Novel dietary interventions focused on fasting, have gained scientific and public attention. Periodic fasting has emerged as a dietary modification promoting beneficial effects on metabolic syndrome. This study aimed to assess whether periodic fasting reduces albuminuria in patients with type 2 diabetes and diabetic nephropathy and determine whether a reduction in albuminuria relates to activation of nephropathy-driven pathways.

Methods Forty patients with type 2 diabetes (HbA1c 7.8±0.2% [62.1±2.3 mmol/mol]) and increased albumin-to-creatinine ratio (ACR) were randomized to fasting-mimicking diet (FMD) (n=21) or Mediterranean diet (n=19) for six months with three-month follow-up. Primary endpoint was the difference of the change in ACR from baseline to after six months between study groups. Subgroup analysis for patients with micro-versus macroalbuminuria at baseline was performed. Secondary endpoints comprised HOMA-IR, circulating markers of dicarbonyl detoxification (MG-H1, glyoxalase-1 and hydroxyacetone), lipid oxidation (acylcarnitines), DNA-damage/repair, (yH2Ax) and senescence (suPAR). Comparison was done by ANCOVA adjusted for age, sex, weight loss and baseline values of the respective outcome.

Results Difference of change in ACR between FMD and control group after six months was 110.3mg/g (95% CI 99.2, 121.5mg/g; P=0.45) in all patients, -30.3mg/g (95% CI -35.7, -24.9mg/g; P≤0.05] in patients with microalbuminuria, and 434.0mg/g (95% CI 404.7, 463.4mg/g; P=0.23) in those with macroalbuminuria at baseline. FMD led to change in HOMA-IR of -3,8 (95% CI -5,6, -2.0; P≤0.05) and in suPAR of - 156.6pg/ml (95% CI -172.9, -140.4pg/ml; P≤0.05) after six months, while no change was observed in markers of dicarbonyl detoxification or DNA-damage/repair. Change in AC profile was related to patient responsiveness to ACR improvement. At follow-up only HOMA-IR reduction (−1.9 [95% CI -3.7, -0.1], P≤0.05) was sustained.

Conclusions When accompanied by intensive diabetes care, FMD improves microalbuminuria, HOMA-IR and suPAR levels. Lack of changes in markers of dicarbonyl detoxification and DNA-damage/repair might explain the relapse of albuminuria at follow-up.

Trial registration German Clinical Trials Register (Deutsches Register Klinischer Studien DRKS), DRKS-ID: DRKS00014287

Competing Interest Statement

The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work. L-Nutra, as funder of the fasting-mimicking diet used in this study, has no role in the design or conduct of the study nor in the preparation, review, or approval of the manuscript. V.L. is founder and shareholder of L-Nutra; his shares are destined to the Create Cures Foundation and other charitable and research organizations.

Clinical Trial

DRKS00014287

Funding Statement

This study was funded by the German Research Foundation (DFG) project number 236360313 (SFB 1118) and project number 255156212 (SFB 1158) as well as by the German Center for Diabetes Research (DZD) project number 82DZD07C2G. The FMD diet used in this study was funded by L-Nutra. All funding bodies had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee of the University Hospital of Heidelberg approved all study procedures (Ethic-Nr. S-682/2016) in compliance with national guidelines and the declaration of Helsinki.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data generated in this study are subject to national data protection laws and are available from the corresponding author upon reasonable request.

  • Abbreviations
    AC
    acylcarnitines
    ACR
    albumin-to-creatinine ratio
    C2
    acetylcarnitine
    CTCAE
    common terminology criteria for adverse events
    DKD
    diabetic kidney disease
    FMD
    fasting-mimicking diet
    FPG
    fasting plasma glucose
    Glo-1
    glyoxalase-1
    MDS
    Mediterranean diet score
    MG
    methylglyoxal
    MG-H1
    methylglyoxal-derived hydroimidazolone 1
    RBC
    red blood cells
    PHQ
    patient health questionnaire
    SF-12
    12-item short-form health survey questionnaire
    SGLT2
    sodium-glucose cotransporter-2
    pGlo-1
    phosphorylated glyoxalase-1
    WBC
    white blood cells
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted December 05, 2021.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    A six-month periodic fasting reduces microalbuminuria and improves metabolic control in patients with type 2 diabetes and diabetic nephropathy: a randomized controlled study
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    A six-month periodic fasting reduces microalbuminuria and improves metabolic control in patients with type 2 diabetes and diabetic nephropathy: a randomized controlled study
    Alba Sulaj, Stefan Kopf, Ekaterina von Rauchhaupt, Elisabeth Kliemank, Maik Brune, Zoltan Kender, Hannelore Bartl, Fabiola Garcia Cortizo, Katarina Klepac, Zhe Han, Varun Kumar, Valter Longo, Aurelio Teleman, Jürgen G. Okun, Jakob Morgenstern, Thomas Fleming, Julia Szendroedi, Stephan Herzig, Peter P. Nawroth
    medRxiv 2021.12.01.21266958; doi: https://doi.org/10.1101/2021.12.01.21266958
    Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    A six-month periodic fasting reduces microalbuminuria and improves metabolic control in patients with type 2 diabetes and diabetic nephropathy: a randomized controlled study
    Alba Sulaj, Stefan Kopf, Ekaterina von Rauchhaupt, Elisabeth Kliemank, Maik Brune, Zoltan Kender, Hannelore Bartl, Fabiola Garcia Cortizo, Katarina Klepac, Zhe Han, Varun Kumar, Valter Longo, Aurelio Teleman, Jürgen G. Okun, Jakob Morgenstern, Thomas Fleming, Julia Szendroedi, Stephan Herzig, Peter P. Nawroth
    medRxiv 2021.12.01.21266958; doi: https://doi.org/10.1101/2021.12.01.21266958

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Endocrinology (including Diabetes Mellitus and Metabolic Disease)
    Subject Areas
    All Articles
    • Addiction Medicine (271)
    • Allergy and Immunology (558)
    • Anesthesia (135)
    • Cardiovascular Medicine (1771)
    • Dentistry and Oral Medicine (239)
    • Dermatology (173)
    • Emergency Medicine (316)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
    • Epidemiology (10816)
    • Forensic Medicine (8)
    • Gastroenterology (595)
    • Genetic and Genomic Medicine (2961)
    • Geriatric Medicine (288)
    • Health Economics (534)
    • Health Informatics (1934)
    • Health Policy (836)
    • Health Systems and Quality Improvement (746)
    • Hematology (293)
    • HIV/AIDS (633)
    • Infectious Diseases (except HIV/AIDS) (12528)
    • Intensive Care and Critical Care Medicine (696)
    • Medical Education (300)
    • Medical Ethics (88)
    • Nephrology (325)
    • Neurology (2812)
    • Nursing (152)
    • Nutrition (433)
    • Obstetrics and Gynecology (560)
    • Occupational and Environmental Health (599)
    • Oncology (1475)
    • Ophthalmology (444)
    • Orthopedics (172)
    • Otolaryngology (257)
    • Pain Medicine (190)
    • Palliative Medicine (56)
    • Pathology (381)
    • Pediatrics (869)
    • Pharmacology and Therapeutics (368)
    • Primary Care Research (339)
    • Psychiatry and Clinical Psychology (2649)
    • Public and Global Health (5384)
    • Radiology and Imaging (1018)
    • Rehabilitation Medicine and Physical Therapy (598)
    • Respiratory Medicine (727)
    • Rheumatology (330)
    • Sexual and Reproductive Health (290)
    • Sports Medicine (279)
    • Surgery (327)
    • Toxicology (48)
    • Transplantation (150)
    • Urology (127)